Global cancer monoclonal antibodies market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for cancer monoclonal antibodies is projected to reach US$ XX Mn by 2023.
Get Sample Copy at https://www.orianresearch.com/request-sample/415623 .
A monoclonal antibody drug in cancer treatments engages natural immune system functions to fight cancer. Cancer monoclonal antibodies may be used in combination with other cancer treatments. An antibody attaches itself to a specific molecule (antigen) on the surface of cancer cell when antibody binds to antigen, it acts as a flag to attract disease-fighting molecules or as a trigger that promotes the destruction of cancer cells by another immune system process. Due to its specificity, monoclonal antibodies have least adverse effects than other cancer treating drugs.
Complete report on Quinidine Sulfate market report spread across 210 pages, profiling 7 companies and supported with tables and figures. Inquire more @ https://www.orianresearch.com/enquiry-before-buying/415623 .
Currently cancer monoclonal antibodies market is witnessing a significant growth. The targeted and combination therapy drugs are leading in the market. Several market player collaborating to develop antibody drugs to treat various type of cancers. In January 2017, AbCellera Biologics, Inc. collaborated with Pfizer Inc. for new therapeutic antibody discovery. AbCellera will use its monoclonal antibody (mAb) screening techniques in the discovery of function
modulating antibodies against undisclosed membrane protein targets. Academic institutions and organisations like National Institute of Health (USA), National Cancer Institute (USA) and many others are collaborating and participating in cancer research and awareness activities.
Global Cancer Monoclonal Antibodies Market:
Global cancer monoclonal antibodies market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for cancer monoclonal antibodies is projected to reach US$ XX Mn by 2023.
Key Players Profiles in The Global Cancer Monoclonal Antibodies Market Include:
• Merck & Co. Inc. (U.S.)
• F. Hoffmann-La Roche AG (Switzerland)
• Spectrum Pharmaceuticals (U.S.)
• Eli Lilly and Company (U.S.)
• Amgen Inc. (U.S.)
• Bristol-Meyer Squibb (U.S.)
• Sanofi (France) and AstraZeneca (U.K.)
Key Features of the Report:
- Executive summary
- Global Cancer Monoclonal Antibodies Market Introduction
- Global Cancer Monoclonal Antibodies Market Dynamics
- Global Cancer Monoclonal Antibodies Market Analysis, 2012 - 2016 and Forecast, 2017 ? 2023
- Global Cancer Monoclonal Antibodies Market, By Application, 2012 - 2016 and Forecast, 2017 - 2023
- Global Cancer Monoclonal Antibodies Market Forecast, By Type of Antibody, 2012 - 2016 and Forecast, 2017 - 2023
- Global Cancer Monoclonal Antibodies Market Forecast, By Conjugation, 2012 - 2016 and Forecast, 2017 - 2023
- Global Cancer Monoclonal Antibodies Market Forecast, By Distribution Channel, 2012 - 2016 and Forecast, 2017 - 2023
- Global Cancer Monoclonal Antibodies Market Forecast, By Region, 2012 - 2016 and Forecast, 2017 - 2023
- North America Cancer Monoclonal Antibodies Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023
…………
By Therapy Type:
• Murine Antibodies
• Humanized Antibodies
• Chimeric Antibodies
By Product Application
• Breast Cancer
• Blood Cancer
• Liver Cancer
• Brain cancer
• Colorectal Cancer
Geographically cancer monoclonal antibodies market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America cancer monoclonal antibodies market is growing at a steady rate due to increased prevalence of various cancers and higher acceptance of existing monoclonal antibodies among healthcare professionals in the region. According to National Cancer Institute (NIH), an estimated 1,685,210 new cases of cancer were diagnosed in the United States and 595,690 people will die from the disease in 2016.
Asia-Pacific region is expected to exhibit rapid growth due to rise in government spending on healthcare infrastructure, increasing R&D spending by companies and growing patient and healthcare professional awareness in therapeutic use of monoclonal antibodies in treatment of cancer. For instance, Government-led fund providers, such as National Natural Science Foundation and?National Basic Research Program of China, offer financial support to enterprises and universities to conduct monoclonal antibody research and development. The presence of healthcare regulations and procedures to promote early treatment of diseases using advanced therapeutics and public policies to support early screening and effective treatments for various cancers is driving the cancer monoclonal antibodies market in Latin-America.
Get Direct Copy of this report @ https://www.orianresearch.com/checkout/415623 .
About Us:
Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the world's most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.
Contact Us:
Ruwin Mendez
Vice President – Global Sales & Partner Relations
Orian Research Consultants
US: +1 (832) 380-8827 | UK: +44 0161-818-8027
Email: info@orianresearch.com
Website: www.orianresearch.com/
Follow Us on LinkedIn: https://www.linkedin.com/company-beta/13281002/